NovoCure (NVCR) Net Cash Flow Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 42.74% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -87.88% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -48.90% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 129.29% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -65.12% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 33.47% |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | -27.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.73% |
| Dec 31, 2025 | -23.40% |
| Sep 30, 2025 | 52.66% |
| Jun 30, 2025 | -49.70% |
| Mar 31, 2025 | -27.13% |
| Dec 31, 2024 | 63.72% |
| Sep 30, 2024 | -60.29% |
| Jun 30, 2024 | -117.89% |
| Mar 31, 2024 | 39.06% |
| Dec 31, 2023 | 100.21% |
| Sep 30, 2023 | -26.48% |
| Jun 30, 2023 | -58.37% |
| Mar 31, 2023 | 176.49% |
| Dec 31, 2022 | -60.22% |
| Sep 30, 2022 | -85.50% |
| Jun 30, 2022 | 84.70% |
| Mar 31, 2022 | -52.39% |
| Dec 31, 2021 | -208.45% |
| Sep 30, 2021 | 238.19% |
| Jun 30, 2021 | 129.78% |
| Mar 31, 2021 | 34.24% |
| Dec 31, 2020 | 71.49% |
| Sep 30, 2020 | 146.78% |
| Jun 30, 2020 | 75.02% |
| Mar 31, 2020 | 30.85% |
| Dec 31, 2019 | -25.45% |
| Sep 30, 2019 | -6.90% |
| Jun 30, 2019 | 40.89% |
| Mar 31, 2019 | 74.81% |
| Dec 31, 2018 | 24.57% |
| Sep 30, 2018 | 30.78% |
| Jun 30, 2018 | -55.46% |
| Mar 31, 2018 | 25.77% |
| Dec 31, 2017 | 46.03% |